Who are Vaximm's investors?

Vaximm's investors include Sunstone Capital.

Vaximm

1 known investors

VAXIMM is a clinical-stage biopharmaceutical company developing oral T-cell immunotherapies for cancer, based on technology invented at UC San Diego. Its lead candidate VXM01 has been evaluated in clinical trials for indications such as pancreatic cancer, and the company operates as a subsidiary of OSR Health.

BiotechDigital HealthHealthtech

Founders & leadership

Andreas NiethammerFounder & Chief Executive Officer

Investors · 1

Sunstone CapitalFrederiksberg

In the news

OSR Health subsidiary completes glioblastoma vaccine analysis By Investing.comca.investing.com · Aug 2026

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level - PharmiWeb.compharmiweb.com · Mar 2026

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestonesprnewswire.com · Nov 2025

Frequently asked questions

What does Vaximm do?: VAXIMM is a clinical-stage biopharmaceutical company developing oral T-cell immunotherapies for cancer, based on technology invented at UC San Diego. Its lead candidate VXM01 has been evaluated in clinical trials for indications such as pancreatic cancer, and the company operates as a subsidiary of OSR Health.
Who are Vaximm's investors?: Vaximm's investors include Sunstone Capital.